30Jul 2023
Safety of sodium‐glucose co‐transporter‐2 inhibitors on amputation across categories of baseline cardiovascular disease and diuretics use in patients with type 2 diabetes

Safety of sodium‐glucose co‐transporter‐2 inhibitors on amputation across categories of baseline cardiovascular disease and diuretics use in patients with type 2 diabetes

The study compared SGLT2is to dipeptidyl peptidase‐4 inhibitors (DPP4is), found significantly lower risks of amputation with SGLT2is in certain patient subgroups, including those with baseline cardiovascular disease and diuretic use. The findings suggest that initiating SGLT2is did not increase amputation risk and can be considered safe for selected high‐risk patients with type 2 diabetes. The results offer reassurance to clinicians regarding SGLT2is safety in vulnerable populations.

  • #endo-diabetology

Like

Save

Share